Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Baram | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel.
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
Tetsuji Yoneo | M | 54 | 12 years | |
Seiji Hirasaki | M | 59 |
AnGes Euro Ltd.
| 18 years |
Yoshinori Oikawa | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel.
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 5 years |
Kazuo Suzuki | M | 67 | 5 years | |
Didi Daboush | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 10 years |
Makoto Hara | M | 73 | 6 years | |
Junichi Komamura | M | 74 | 12 years | |
Todd Wider | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 6 years |
Norikazu Eiki | M | 76 | 10 years | |
Jun Sakurai | M | - | - | |
Lior Izhar | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
Rachel Diamant | F | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
Joseph Oved | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 2 years |
Tetsuharu Yoneo | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Stephen P. Squinto | M | 67 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Robbie Woodman | M | 47 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Hajime Watanabe | M | - | - | |
Earn Perry | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | - |
Carl Gordon | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Chaim Hurvitz | M | 63 |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 6 years |
Erez Chimovits | M | 60 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Dorit Rozner | M | - |
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Koji Nakamoto | M | 70 | - | |
Ichiro Kitasato | M | 91 | 10 years | |
Shunsuke Sami | M | 70 | - | |
Richard Lowenthal | M | 58 | 1 years | |
Tadashi Hishida | M | 81 | - | |
Lee-Cheng Liu | M | - | - | |
Shirow Enoki | M | 86 | - | |
Noriaki Ohmura | M | 80 | - | |
Christine Silverstein | F | 41 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Zhi Feng Long | M | 62 | 8 years | |
Diana Halim | F | 47 | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
Japan | 18 | 52.94% |
United States | 12 | 35.29% |
Israel | 6 | 17.65% |
United Kingdom | 1 | 2.94% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ei Yamada
- Personal Network